Navigation Links
Improved Meningitis Vaccine for Africa Expected to End Deadly Scourge

The Meningitis Vaccine Project (MVP) today released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine-- expected to sell initially for 40 cents a dose --will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region.

MVP, a partnership between the World Health Organization (WHO) and the Seattle-based non-profit, PATH, is collaborating with Pune-based vaccine producer, Serum Institute of India Limited (SIIL), to produce the new vaccine against serogroup A Neisseria meningitidis (meningococcus).

The preliminary results of their study, a Phase II vaccine trial, reveal that the vaccine could eventually slash the incidence of epidemics in the meningitis belt, as 21 affected nations of sub-Saharan Africa are collectively known. The vaccine is expected to block infection by the serogroup A meningococcus, and therefore extend protection to the entire population, including the unvaccinated, a phenomenon know as herd immunity.

The new meningococcal conjugate vaccine trial, in 12- to 23-month-olds in Mali and The Gambia, shows that the vaccine was safe, and that it produced antibody levels almost 20 times higher than those obtained with the marketed polysaccharide (un-conjugated) vaccine. This means that protection from serogroup A meningococcal meningitis is expected to last for several years.

"This important study brings real hope that the lives of thousands of children, teenagers, and young adults will be saved by immunization and that widespread suffering, sickness and socioeconomic disruption can be avoided, said Dr. Margaret Chan, Director-General of the World Health Organization in a statement.

As a result of the encouraging preliminary findings of this Phase II clinical study, SIIL and MVP will proceed with a Phase 2/3 study where the vaccine will be tested in 2- to 29 -year-oldsthe population that will be mostly targeted by mass vaccination campaigns. Testing will take place in Mali, The Gambia, and at least one other African country. An additional clinical study is planned for this summer in India, where the vaccine will be licensed.

A total of 600 toddlers participated in the Phase II study. They were enrolled at two clinical sites in Africa: Center for Vaccine Development (CVD)-Mali and the Medical Research Council (MRC) Laboratories in The Gambia.

Dr. Brown Okoko, principal investigator at the MRC site in Basse, said, The clinical teams at MRC and CVD-Mali identify with the vision, mission, and mandate of the Meningitis Vaccine Project. We are all highly motivated and very proud to be able to contribute to the development of a vaccine that is critically needed in Africa.

Some of the families who participated in the study have lost several members of their family to meningococcal meningitis. Those who have not been directly affected know the terrible impact that the disease has on the community. There is a lot of support for the clinical study and the new vaccine in the Bamako community, said Dr. Samba Sow, principal investigator at CVD-Mali.

Meningitis is an infection of the meninges, the thin lining that surrounds the brain and spinal cord. It is one of the world's most dreaded infectious diseases. Even with antibiotic treatment, at least 10 percent of patients die, with up to 20 percent left with permanent problems, such as mental retardation, deafness, epilepsy, or necrosis leading to limb amputation.

The most prominent groups of meningococci are A, B, C, Y, and W135. While groups A, B, and C are responsible for the majority of cases worldwide, group A causes deadly, explosive epidemics every 8 to 10 years predominantly in what is known as the African meningitis belt, an area that stretches from Senegal and The Gambia in the West to Ethiopia in the East.

The belt has an at-risk population of about 430 million. The largest epidemic wave ever recorded in history swept across the entire region in 19961997, causing over 250,000 cases and 25,000 deaths.

Africa has been relatively spared in recent years, but last year's 41,526 reported cases and the 47,925 cases reported from January 1 to May 6, 2007 bring the fear that a new epidemic wave may have begun in sub-Saharan Africa.


'"/>




Related medicine news :

1. Improved height from administration of growth hormones
2. Improved procedure to do laproscopic esophagectomy discovered
3. Improved parent-physician communication to prevent hospitalizations for childhood asthma
4. Testicular Cancer Patients Have Improved Reproductive Outcomes After Treatment
5. Improved cure and activity level seen among patients treated by Vertebroplasty.
6. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
7. Minister claims Chinas Epidemic Control System Improved
8. Quality Platelets and Improved Blood Availability No Longer a Pipe Dream
9. Robotic Assisted Knee Replacement Surgery Has Improved Accuracy
10. Latest Version of Echocardiography Provides Improved Pictures of the Heart
11. Improved Bone Grafts With Bioactive cement scaffold
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: